Search results
Unpacking Averages: Growth of AL/ML in Medicine as Evidenced by Clinical Trials
The National Law Review· 1 day agoMost people have seen the growth in artificial intelligence/ machine learning (AI/ML)-based medical...
New Clinical Assessment Tool Improves Dementia Care Actions in Primary Care Patients, NIH Reports
Sierra Sun Times· 15 hours agoResource tripled the odds of receiving dementia-related care within 90 days. June 5, 2024 – A...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 3 days agoFlamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC) PR Newswire LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, June 2, 2024 -Trial-in-Progress poster provides
The Push to Get More People Into Long COVID Studies
Medscape· 2 days agoWhen Ezra Spier was diagnosed with long COVID in late 2022, his main symptom, postexertional malaise, caused fatigue so severe that it forced him to quit...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 3 days agoTelix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and ...
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in...
Morningstar· 2 days ago- At Month 18, there was a statistically significant improvement in body proportionality (p-value of 0.001). PALO ALTO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq ...
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors...
The Woonsocket Call· 5 days agoEli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors ...
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a...
Morningstar· 6 days agoBiogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has granted marketing authorization under exceptional circumstances and maintained orphan designation for QALSODY® (tofersen ...
Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer...
Nature· 6 days agoEthical approval to generate patient-derived models was obtained through the Tracking Cancer Evolution through Therapy (TRACERx) clinical study (REC reference: 13/LO/1546; https://clinicaltrials ...
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study...
KOIN News 6 Portland· 3 days agoThe abstract was selected for ASCO Daily News coverage.